microRNAs Promoting Growth of Gastric Cancer Xenografts and Correlation to Clinical Prognosis

Autor:	Ulrich H. Weidle, Fabian Birzele, Adam Nopora
Rok vydání:	2021
Předmět:	Male Cancer Research business.industry Cancer Review Article Prognosis medicine.disease Biochemistry Correlation MicroRNAs Clinical prognosis Stomach Neoplasms Apoptosis microRNA Genetics Cancer research Heterografts Humans Medicine Female business Molecular Biology
Zdroj:	Cancer Genomics Proteomics
ISSN:	1790-6245 1109-6535
DOI:	10.21873/cgp.20237
Popis:	The annual death toll for gastric cancer is in the range of 700,000 worldwide. Even in patients with early-stage gastric cancer recurrence within five years has been observed after surgical resection and following chemotherapy with therapy-resistant features. Therefore, the identification of new targets and treatment modalities for gastric cancer is of paramount importance. In this review we focus on the role of microRNAs with documented efficacy in preclinical xenograft models with respect to growth of human gastric cancer cells. We have identified 31 miRs (-10b, -19a, -19b, -20a, -23a/b, -25, -27a-3p, -92a, -93, -100, -106a, -130a, -135a, -135b-5p, -151-5p, -187, -199-3p, -215, -221-3p, -224, -340a, -382, -421, -425, -487a, -493, -532-3p, -575, -589, -664a-3p) covering 26 different targets which promote growth of gastric cancer cells in vitro and in vivo as xenografts. Five miRs (miRs -10b, 151-5p, -187, 532-3p and -589) additionally have an impact on metastasis. Thirteen of the identified miRs (-19b, -20a/b, -25, -92a, -106a, -135a, -187, -221-3p, -340a, -421, -493, -575 and -589) have clinical impact on worse prognosis in patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee0793e92d9dfa54bce94aace332c5b https://doi.org/10.21873/cgp.20237 Zobrazit plný text záznamu